Cue Biopharma Books $153M Loss as Ascendant Warrant Accounting Dominates Q2
Turnaround
Company Background
Cue Biopharma is a Boston-based clinical-stage biopharmaceutical company with a market capitalization of approximately $127.8 million. Until mid-2026 its primary asset was the Immuno-STAT platform, a T-cell modulation approach focused on autoimmune disease; the platform's lead candidate, CUE-401, remains in pre-IND development. The company has had three chief executives in under a year: Usman Azam was appointed in September 2025, resigned in March 2026, was replaced on an interim basis by CFO Lucinda Warren, and succeeded by Dr. Shao-Lee Lin on April 30, 2026. A 1-for-30 reverse stock split was effected on April 23, 2026 to satisfy Nasdaq minimum bid price requirements.
Full-year 2025 revenue was $27.5 million, sharply higher than $9.3 million in 2024, driven primarily by a collaboration and license deal with ImmunoScape signed in November 2025. That deal granted ImmunoScape rights to Cue's CUE-100 Series oncology molecules in exchange for $15 million in upfront payments, a 40% equity stake in ImmunoScape, and royalties. As of December 31, 2025, the company held $27.1 million in cash, and its forward-looking disclosures have consistently flagged a going-concern risk — the company has stated it does not have sufficient capital to continue operations beyond twelve months without additional financing.
Dr. Lin's appointment coincided on the same day with Cue's largest strategic move in its history: the April 30, 2026 license of Ascendant-221, a clinical-stage anti-IgE antibody, from Ascendant Health Sciences Ltd. The deal effectively repositioned the company from a T-cell oncology platform into a broader immunology and allergy portfolio, a strategic shift that carried substantial upfront costs and complex accounting consequences.
What Was Disclosed
Q2 2026 revenue was $7.9 million, up from $3.0 million in the prior-year period, driven by a preclinical milestone payment triggered under the Boehringer Ingelheim collaboration. The net loss was $153.1 million, an 18-fold increase from Q2 2025, with virtually the entire increment attributable to costs and charges arising from the Ascendant transaction.
The most consequential single item was a $90.0 million loss on the issuance of liability-classified warrants, which sat in other expense. Under the accounting treatment applied, the warrants issued to Ascendant Health Sciences as partial license consideration were classified as liabilities rather than equity, requiring them to be measured at fair value at issuance; the difference between their fair value and the carrying value of the consideration was recognized immediately as a loss. A $24.5 million gain from subsequent changes in the fair value of those same instruments partially offset the initial charge, leaving a net non-cash hit from the warrant accounting of approximately $65.4 million in other expense for the quarter. R&D expense was $49.0 million, compared with $7.9 million a year earlier; management attributed roughly $20 million to one-time cash payments including the $15.0 million upfront license fee to Ascendant and transaction costs, and a further approximately $20 million to the non-cash fair value of warrants issued to Ascendant, with a corresponding credit to shareholders' equity that produced no net impact on stockholders' equity. G&A reached $46.6 million versus $3.7 million in Q2 2025, with management citing approximately $23.0 million related to integration costs and the newly assembled management team, alongside $19.7 million in non-cash stock-based compensation. CEO Lin's employment agreement disclosed a fully-vested RSU grant for 327,537 shares — with the company paying withholding taxes on a grossed-up basis — plus options for 655,074 shares, which accounts for a substantial portion of that stock compensation charge.
As of June 30, 2026, cash and cash equivalents stood at $17.4 million. Liabilities had risen to $28.4 million from $15.8 million at year-end 2025, reflecting in part the warrant liabilities on the balance sheet. Stockholders' equity contracted to $2.3 million from $26.4 million. Subsequent to quarter-end, the company completed a $50.0 million private placement at $33.21 per share, led by Cormorant Asset Management with participation from Columbia Threadneedle Investments, which closed July 13, 2026.
Why It Matters
The headline loss figure of $153.1 million is almost entirely non-cash and transactional, which matters for understanding the company's operational position — but it does not make the accounting inconsequential. The $90.0 million warrant-issuance loss reflects the market's real-time valuation of what Cue gave away to secure the Ascendant license: warrants that, at the time of grant, were worth $90 million more than the offsetting consideration on the books. That is the price of the deal as the market priced it on day one. The subsequent $24.5 million gain shows the warrants declined in value by quarter-end, but the net economic transfer implied by the initial issuance loss remains substantial relative to a company of Cue's size.
The going-concern language that has appeared in every major disclosure since at least late 2025 has not been formally resolved. The April 30 Ascendant license simultaneously created the quarter's loss and was the catalyst for the $50.0 million PIPE financing that followed. That capital raise, at $33.21 per share versus the April PIPE's effective price of $11.00, represents a significant price appreciation in a short window — but it also means the company's capital structure has been materially reshaped through several layers of dilutive transactions in rapid succession: the December 2025 underwritten offering, the April 2026 PIPE, the Ascendant warrant issuance, and the July 2026 PIPE. The $50 million raised from Cormorant and Columbia Threadneedle, if it resolves the going-concern question, is the more important near-term data point than the Q2 loss figure.
The company's pipeline now rests on two main assets: CUE-221 (Ascendant-221 renamed), for which an IND was recently submitted to the FDA in food allergy, and CUE-401, the original Immuno-STAT autoimmune candidate, still targeting IND submission and Phase 1 initiation by year-end 2026. Phase 2 data from Ascendant Health's China CSU study is expected by the end of Q3 2026; that readout will determine whether Cue proceeds with a global Phase 2b trial in food allergy and whether the strategic logic of the entire acquisition holds up.